Island Pharmaceuticals Limited

Equities

ILA

AU0000138869

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 06:43:10 03/07/2024 am IST			5-day change	1st Jan Change
0.072 ^AUD	-6.49%		-6.49%	-24.21%

03/07	Island Pharmaceuticals Acquiring Clinical-Stage Antiviral Molecule	MT
08/05	Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13%	MT

Island Pharmaceuticals targets Mosquito-borne viruses with antiviral pipeline

December 22, 2022 at 01:01 am IST

EQS-News: Island Pharmaceuticals Ltd
Island Pharmaceuticals targets Mosquito-borne viruses with antiviral pipeline

21.12.2022 / 20:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

News Source: News Direct

21.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language:	English
Company:	Island Pharmaceuticals Ltd


	United States
ISIN:	AU0000138869
EQS News ID:	1519411


End of News	EQS News Service

1519411 21.12.2022 CET/CEST

Latest news about Island Pharmaceuticals Limited

Island Pharmaceuticals Acquiring Clinical-Stage Antiviral Molecule	03/07	MT
Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13%	08/05	MT
Island Pharmaceuticals Reports Positive Data from Dose Study of Dengue Medication	16/04	MT
Island Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	26/02	CI
Australia Shares Fall as Central Bank Keeps Rates Steady	06/02	MT
Island Pharmaceuticals Achieves Primary Endpoint in Dengue Drug Ascending Dose Study	06/02	MT
Island Pharmaceuticals Doses Subjects with Third Cohort for Dengue Medication Study	19/01	MT
Island Pharmaceuticals' ISLA-101 Study Advances to Third Cohort Dosing	26/12	MT
Island Pharmaceuticals Signs R&D Loan Deal With Radium Capital	15/12	MT
Island Pharmaceuticals Announces Change of Company Secretaries	01/12	CI
Island Pharmaceuticals Administers First Drug Cohort for Dengue Medication Study	24/11	MT
Island Pharmaceuticals Begins Screening for Dengue Medication Study	13/11	MT
Island Pharmaceuticals Gets Nearly AU$390,000 R&D Tax Rebate; Shares Fall 4%	10/11	MT
Island Pharmaceuticals Receives Ethics Approval for Ascending Dose Study	07/11	MT
Island Pharmaceuticals Secures Australian Patent for Flavivirus Treatment	02/11	MT
Island Pharmaceuticals to Start Dengue Drug Trial in October	26/23/26	MT
Island Pharmaceuticals Secures US Patent to Support Dengue Medication	13/23/13	MT
Island Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Island Pharmaceuticals Secures US Grant Funding to Bolster ISLA-101 Clinical Development	07/23/07	MT
Island Pharmaceuticals Secures FDA Clearance for ISLA-101 Program for Mosquito-Borne Diseases	16/23/16	MT
8,195,943 Options of Island Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 13-APR-2023.	13/23/13	CI
38,022,140 Ordinary Shares of Island Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 13-APR-2023.	13/23/13	CI
Island Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23/23/23	CI
US FDA Places Island Pharmaceuticals' Phase 2A Clinical Trial for Dengue Treatment Under Clinical Hold	01/23/01	MT
Island Pharmaceuticals Ltd Receives Additional FDA Feedback on IND for ISLA-101 Phase 2a Clinical Study	01/23/01	CI

Chart Island Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Island Pharmaceuticals Limited is an Australia-based drug repurposing company, focused on areas of need for antiviral therapeutics to address infectious diseases. The Company's lead asset is ISLA-101, a drug, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.

Sector

Biotechnology & Medical Research

Calendar

22/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ISLAND PHARMACEUTICALS LIMITED	-24.21%	59.7L
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	12TCr
REGENERON PHARMACEUTICALS, INC.	+16.60%	11TCr
ARGENX SE	+17.55%	2.62TCr
BIONTECH SE	-24.33%	1.9TCr
GENMAB A/S	-19.14%	1.57TCr
BEIGENE, LTD.	-17.95%	1.52TCr
WUXI APPTEC CO., LTD.	-46.81%	1.47TCr
SAREPTA THERAPEUTICS, INC.	+58.78%	1.46TCr
NEUROCRINE BIOSCIENCES, INC.	+4.91%	1.38TCr

Bio Therapeutic Drugs

Island Pharmaceuticals Limited

Equities

ILA

AU0000138869

Biotechnology & Medical Research

Island Pharmaceuticals targets Mosquito-borne viruses with antiviral pipeline

Latest news about Island Pharmaceuticals Limited

Chart Island Pharmaceuticals Limited

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs